Total Payments
$33,014
2024 Payments
$14,249
Companies
18
Transactions
82
Medicare Patients
2,619
Medicare Billing
$433,430
Payment Breakdown by Category
Consulting$24,883 (75.4%)
Other$3,613 (10.9%)
Travel$3,212 (9.7%)
Food & Beverage$1,214 (3.7%)
Education$92.67 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,883 | 10 | 75.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,613 | 4 | 10.9% |
| Travel and Lodging | $3,212 | 10 | 9.7% |
| Food and Beverage | $1,214 | 54 | 3.7% |
| Education | $92.67 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARGENX US, INC. | $27,369 | 41 | $0 (2024) |
| UCB, Inc. | $3,467 | 11 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $1,772 | 4 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $64.49 | 4 | $0 (2018) |
| Grifols USA, LLC | $52.53 | 3 | $0 (2022) |
| GENZYME CORPORATION | $46.04 | 2 | $0 (2017) |
| Avanir Pharmaceuticals, Inc. | $34.97 | 2 | $0 (2017) |
| Acorda Therapeutics, Inc | $33.00 | 2 | $0 (2017) |
| Xeris Pharmaceuticals, Inc. | $28.72 | 2 | $0 (2023) |
| CSL Behring | $23.19 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,249 | 25 | ARGENX US, INC. ($9,115) |
| 2023 | $8,146 | 19 | ARGENX US, INC. ($8,067) |
| 2022 | $10,267 | 17 | ARGENX US, INC. ($10,187) |
| 2021 | $46.32 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($20.07) |
| 2020 | $23.19 | 2 | CSL Behring ($23.19) |
| 2019 | $12.73 | 1 | Mallinckrodt Enterprises LLC ($12.73) |
| 2018 | $33.99 | 2 | Lilly USA, LLC ($19.44) |
| 2017 | $235.54 | 13 | UCB, Inc. ($55.90) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Neurology | ||||||
| 11/13/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Neurology | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: Neurology | ||||||
| 10/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Neurology | ||||||
| 09/25/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: Neurology | ||||||
| 09/24/2024 | UCB, Inc. | Zilbrysq (Biological) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: Neurology | ||||||
| 09/17/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 09/04/2024 | UCB, Inc. | Rystiggo (Drug) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: Neurology | ||||||
| 09/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Neurology | ||||||
| 07/29/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Neurology | ||||||
| 07/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $820.94 | General |
| Category: Neurology | ||||||
| 07/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: Neurology | ||||||
| 07/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Neurology | ||||||
| 07/16/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $515.39 | General |
| Category: Neurology | ||||||
| 07/16/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $95.18 | General |
| Category: Neurology | ||||||
| 07/09/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $407.96 | General |
| Category: Neurology | ||||||
| 07/08/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: Neurology | ||||||
| 06/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $1,715.00 | General |
| Category: Rare Disease | ||||||
| 06/05/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: Neurology | ||||||
| 05/21/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Neurology | ||||||
| 04/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: Rare Disease | ||||||
| 03/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Neurology | ||||||
| 03/01/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: Neurology | ||||||
| 02/21/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Neurology | ||||||
| 01/16/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 721 | 1,483 | $527,003 | $135,785 |
| 2022 | 12 | 627 | 1,113 | $385,307 | $100,828 |
| 2021 | 12 | 687 | 1,150 | $406,787 | $109,727 |
| 2020 | 10 | 584 | 1,010 | $353,257 | $87,089 |
Total Patients
2,619
Total Services
4,756
Medicare Billing
$433,430
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 214 | 706 | $241,643 | $67,875 | 28.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 154 | 355 | $84,859 | $22,748 | 26.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 148 | 152 | $101,227 | $20,374 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 70 | 126 | $45,531 | $11,837 | 26.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 52 | $23,632 | $5,404 | 22.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $12,108 | $2,344 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 22 | $5,415 | $1,661 | 30.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 15 | 16 | $2,468 | $1,345 | 54.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $7,155 | $1,300 | 18.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 13 | 19 | $2,965 | $896.80 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 184 | 524 | $179,349 | $45,017 | 25.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 87 | 87 | $57,939 | $14,171 | 24.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 98 | 187 | $44,700 | $11,316 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 107 | $38,764 | $10,367 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $19,813 | $5,227 | 26.4% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 16 | 16 | $8,494 | $3,685 | 43.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 22 | $9,998 | $2,490 | 24.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 21 | 32 | $8,146 | $2,392 | 29.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 23 | 24 | $3,702 | $2,247 | 60.7% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 31 | 42 | $6,555 | $1,510 | 23.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 19 | $4,676 | $1,379 | 29.5% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 13 | 17 | $3,170 | $1,028 | 32.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 176 | 461 | $157,786 | $41,220 | 26.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 118 | 119 | $79,250 | $20,277 | 25.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 138 | 282 | $67,409 | $17,310 | 25.7% |
About Dr. Beth Stein, MD
Dr. Beth Stein, MD is a Neurology healthcare provider based in Paterson, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1710146865.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Beth Stein, MD has received a total of $33,014 in payments from pharmaceutical and medical device companies, with $14,249 received in 2024. These payments were reported across 82 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($24,883).
As a Medicare-enrolled provider, Stein has provided services to 2,619 Medicare beneficiaries, totaling 4,756 services with total Medicare billing of $433,430. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuromuscular Medicine
- Location Paterson, NJ
- Active Since 06/04/2008
- Last Updated 06/06/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1710146865
Products in Payments
- VYVGART (Drug) $14,869
- VYVGART HYTRULO (Drug) $7,650
- Rystiggo (Drug) $2,552
- ULTOMIRIS (Biological) $1,756
- Zilbrysq (Biological) $840.00
- NUPLAZID (Drug) $64.49
- Briviact (Drug) $55.90
- Gamunex-C (Biological) $52.53
- AUBAGIO (Drug) $46.04
- AMPYRA (Drug) $33.00
- KEVEYIS (Drug) $28.72
- Hizentra (Biological) $23.19
- VYVANSE (Drug) $20.07
- TRULICITY (Drug) $19.44
- Zilbrysq (Drug) $19.26
- NUEDEXTA (Drug) $17.53
- ONZETRA Xsail (Drug) $17.44
- UBRELVY (Drug) $16.64
- SOLIRIS (Drug) $15.69
- Lenvima (Drug) $14.56
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.